Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 283.00
Bid: 283.00
Ask: 285.00
Change: -10.00 (-3.41%)
Spread: 2.00 (0.707%)
Open: 285.00
High: 285.00
Low: 283.00
Prev. Close: 293.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hutchmed China confident after being added to SEC list

Thu, 31st Mar 2022 10:04

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

The AIM-traded firm said that, following its implementation of rules under the act, the US Securities and Exchange Commission (SEC) added Hutchmed to its list of issuers identified under the act.

It was provisionally named as an SEC-identified Issuer on 8 March, following the filing of its annual report on 3 March.

The SEC estimated that 273 registrants might be identified under the act as part of its review of registrants in 2020.

"We anticipate that other similarly-situated US-listed companies with operations in Hong Kong and other parts of China will be added once they file their annual reports with the SEC," the board said in its statement.

"As the company continues to monitor market developments and evaluate all strategic options, with the appropriate counsel and guidance, it would like to note that this update has no impact on business operations."

Hutchmed said it understood that the motivation behind the act was to ensure appropriate transparency and disclosure, so that investors would be able to make informed investment decisions.

"This we fully support and have been committed to ever since our initial listing in London in 2006.

"As always, we will continue complying with relevant laws and regulations in all the jurisdictions we are listed.

"Furthermore, we are working to maintain communication with the China Securities Regulatory Commission (CSRC) to understand if there are further updates on their discussions with the US authorities regarding how China-based companies may be able to meet the requirements of the act."

Hutchmed said it would continue to evaluate its options to remain listed in the US, including assessing the merits of appointing an auditor outside of China if and when the contribution of its international business to the group exceeded its China business.

At 1235 BST, shares in Hutchmed China were down 3.49% in London, at 290.5p.

More News
25 Nov 2019 13:47

Hutchison China MediTech Gets Orphan Designation For Surufatinib

Hutchison China MediTech Gets Orphan Designation For Surufatinib

Read more
12 Nov 2019 12:19

CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review

CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review

Read more
11 Nov 2019 11:08

Hutchison's Surufatinib Gets New Drug Application Approval In China

Hutchison's Surufatinib Gets New Drug Application Approval In China

Read more
10 Oct 2019 15:45

Hutchison China Meditech expands collaboration with Innovent

(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..

Read more
10 Oct 2019 12:43

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Read more
4 Oct 2019 15:21

Hutchison Chi-Med initiates latest study of HMPL-523

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.

Read more
4 Oct 2019 10:26

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

Read more
4 Oct 2019 08:39

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Read more
3 Sep 2019 13:25

Hutchison China Starts Trial For HMPL-689 On Lymphoma Treatment

(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at

Read more
23 Aug 2019 11:25

Hutchison China MediTech launches trial for autoimmune disorder treatment

(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.

Read more
23 Aug 2019 10:59

Hutchison China Meditech Starts HMPL-523 Trial In China

(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last

Read more
30 Jul 2019 11:43

Hutchison China Interim Loss Widens On Expenses; Alters 2019 Guidance

(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares

Read more
23 Jul 2019 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 24 July Tullow OilHalf Year ResultsPaypointQ1 Year ResultsLaw

Read more
3 Jul 2019 13:42

Prudential Holds 5% Hutchison China Meditech Stake After Deal

(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in

Read more
28 Jun 2019 16:38

Hutchison China Meditech Confirms Discounted Nasdaq Offer Pricing

(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.